Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1779-1784
JournalBlood
Volume115
Issue number9
DOIs
Publication statusPublished - 2010

Cite this